Երկիր: Կանադա
Լեզու: անգլերեն
Աղբյուրը: Health Canada
METHYLNALTREXONE BROMIDE
SALIX PHARMACEUTICALS INC
A06AH01
METHYLNALTREXONE BROMIDE
20MG
SOLUTION
METHYLNALTREXONE BROMIDE 20MG
SUBCUTANEOUS
0.6ML
Prescription
MISCELLANEOUS GI DRUGS
Active ingredient group (AIG) number: 0152456001; AHFS:
APPROVED
2010-09-17
_ _ PRODUCT MONOGRAPH PR RELISTOR ® Methylnaltrexone bromide injection, 20 mg /mL For Subcutaneous use μ-opioid receptor antagonist Salix Pharmaceuticals, a division of Valeant Pharmaceuticals North America, LLC 400 Somerset Corporate Boulevard Bridgewater, NJ 08807 Date of Revision: July 25, 2018 Submission Control No: 208302 _ _ _RELISTOR_ _® _ _Product Monograph _ _ _ _Page 2 of 70_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION................................................................3 SUMMARY PRODUCT INFORMATION ....................................................................................3 INDICATIONS AND CLINICAL USE ..........................................................................................3 CONTRAINDICATIONS ...............................................................................................................4 WARNINGS AND PRECAUTIONS ..............................................................................................4 ADVERSE REACTIONS ................................................................................................................6 DRUG INTERACTIONS ..............................................................................................................18 DOSAGE AND ADMINISTRATION ..........................................................................................19 ACTION AND CLINICAL PHARMACOLOGY ........................................................................21 STORAGE AND STABILITY ......................................................................................................25 SPECIAL HANDLING INSTRUCTIONS ...................................................................................25 DOSAGE FORMS, COMPOSITION AND PACKAGING .........................................................25 PART II: SCIENTIFIC INFORMATION .....................................................................................28 PHARMACEUTICAL INFORMATION .................................................................. Կարդացեք ամբողջական փաստաթուղթը